Amphastar Pharmaceuticals, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:AMPH
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 632 out of 850
Universe
Global Universe 12175 out of 15080
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| The United Laboratories International Holdings Ltd. |
27.8
Medium
|
374 out of 850 |
| Tsumura & Co. |
31.3
High
|
545 out of 850 |
| Chengdu Kanghong Pharmaceutical Group Co., Ltd. |
31.7
High
|
553 out of 850 |
| Amphastar Pharmaceuticals, Inc. |
33.4
High
|
632 out of 850 |
| Hubei Biocause Pharmaceutical Co., Ltd. |
39.5
High
|
814 out of 850 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted Amphastar Pharmaceuticals, Inc.'s ESG Risk Rating in the last three years
Highest Controversy Level
Contributing Events
Highest Controversy Events Locations
